It was found that HGF induced resistance to reversible, irreversible, and even mutant-selective EGFR-TKIs by restoring MetGab1/PI3K/Akt pathway [11–14], indicating that HGF is an important therapeutic target for overcoming tumor resistance to EGFR-TKIs. This evidence concerns the gene EGFR and neoplasm.